CSL和Arcturus的ARCT-154疫苗的免疫反应比日本的一项有828人参加的研究显示Pfizer的Comirnaty的剂量较低、剂量较低的Comernaty的免疫反应更强大、更持久。 ARCT-154 vaccine by CSL and Arcturus showed stronger, longer-lasting immune response than Pfizer's Comirnaty, with a lower dose, in a Japanese study involving 828 participants.

由CSL公司和Arcturus治疗公司开发的自我强化的MRNA COVID-19疫苗ARCT-154显示,一年的免疫反应比Pfizer的Comirnaty更强,即使剂量较低(5微克对30微克)。 A self-amplifying mRNA COVID-19 vaccine, ARCT-154, developed by CSL and Arcturus Therapeutics, showed a stronger immune response than Pfizer's Comirnaty for up to a year, even at a lower dose (5 μg vs. 30 μg). 该研究在日本进行,有828人参加,表明ARCT-154对各种SARS-CoV-2菌株有效。 Conducted in Japan with 828 participants, the study indicated that ARCT-154 is effective against various SARS-CoV-2 strains. 日本批准的疫苗表明,与常规的MRNA疫苗相比,保护期延长。 The vaccine, approved in Japan, suggests enhanced protection duration compared to conventional mRNA vaccines.